Refeed Night, Receptors Unreachable

You scheduled the cheat meal. Your hypothalamus did not RSVP.

Filed under Survodutide ·Neuropeptide Y ·Cagrilintide · #glp-1 ·#refeed ·#cope

Active Compounds

Survodutide · Dual Glucagon/GLP-1 Receptor Agonist

An investigational dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim and Zealand Pharma. Phase 3 SYNCHRONIZE-1 (April 28, 2026 topline) achieved 16.6% mean weight loss at 76 weeks — the first positive Phase 3 readout in the SYNCHRONIZE obesity program. FDA Fast Track (2021) and Breakthrough Therapy (2024) designations for MASH; full SYNCHRONIZE-1 data at ADA June 2026.

Neuropeptide Y · Neuropeptide / Orexigenic Hormone

A 36-amino-acid endogenous neuropeptide, one of the most abundant in the mammalian brain and the central nervous system's primary orexigenic (hunger-driving) signal.

Cagrilintide · Amylin Analogue

A long-acting amylin analogue being developed in combination with semaglutide (CagriSema) for enhanced weight loss.

RX: Survodutide · Neuropeptide Y · Cagrilintide
Dosage: ½ sweet potato PO, observed
Half-life: longer than your appetite
Source: manual
Tags: glp-1 , refeed , cope
Stamped: 2026-05-11 · Cycle 019
Lot #: LOT-20260511T16:04:35.068Z